ATH-1020 is under clinical development by Athira Pharma and currently in Phase I for Depression. According to GlobalData, Phase I drugs for Depression have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ATH-1020’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ATH-1020 overview

ATH-1020 is under development for the treatment of neuropsychiatric indications including anxiety disorders, depression and schizophrenia, neuropathic pain and neurodegenerative diseases. It is administered by the oral route formulated as a capsule. It acts by targeting hepatocyte growth factor and hepatocyte growth factor receptor (MET).

Athira Pharma overview

Athira Pharma is a biopharmaceutical company that develops small molecules to treat neurodegenerative diseases and restore neuronal health. Its pipeline candidates include ATH-1020 treats neurodegenerative diseases, ATH-1105 treats amyotrophic lateral sclerosis; Fosgonimeton treats Parkinson’s disease, dementia and dementia with lewy bodies and early compounds treats neurodegenerative diseases. The company works in partnership with contract development and manufacturing organizations to manufacture and supply preclinical and clinical materials for the development of product candidates. Athira Pharma is headquartered in Bothell, Washington, the US.

For a complete picture of ATH-1020’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.